The Next Agonist
Who would pay for the trial: the sponsor problem
Analysis. The prevention-trial piece explains why the mountain is expensive. This one is about the expedition’s invoice — who would actually pay it, and why the company that already owns the molecule is not in the queue.
The middle-ground agonist already exists. Afamelanotide is approved, tested, and on the market. What this site keeps pointing at — a photoprotective melanocortin drug for ordinary skin — is not a chemistry problem looking for a lab. It is a finance problem looking for a sponsor. Those are different vacancies, and they have been confused for twenty years.
A sponsor is not a believer. A sponsor is an institution that will write the checks for a trial large enough, long enough, and clean enough that a regulator will let healthy people take the drug. The gray market never needed one. An approved general-public agonist cannot exist without one.
The incumbent already answered
Clinuvel Pharmaceuticals is not a hypothetical. It is the sponsor the Arizona work eventually got. In its 2026 U.S. registration statement, sales of Scenesse to treat erythropoietic protoporphyria accounted for $61.1 million in the year to June 2025 — more than 90 percent of product revenue — and $24.2 million in the following six months, still more than 90 percent. Nine consecutive years of profit. U.S. orphan exclusivity runs to October 2026; the European orphan clock already ran out, and no generic manufacturer has walked in.
That is a working rare-disease business. Few patients, a clinic-administered implant, a price the specialty system will bear, a sales force that knows every porphyria centre. It is also, by construction, the opposite of a plan to dose millions of healthy people for a decade and prove they got less skin cancer.
Look at where the cash actually goes. The next pharmaceutical bet is vitiligo — a 200-patient Phase III, a reimbursable dermatology indication, a topline the regulatory tracker has on the calendar for December 2026. The diversification bet, named in the same registration statement, is not a prevention NDA. It is a cosmetics line based on melanocortin technology: the company that owns the only systemic photoprotective drug on earth intends to “tap into the cosmetic industry” so it is less dependent on a single rare-disease segment. Cosmetics do not require a cancer-prevention trial. That is the point of cosmetics.
This is not a moral failure. It is capital allocation. Clinuvel’s cash reserves at the 2025 year-end were on the order of $150 million. Novo Nordisk ran SELECT — the cardiovascular-outcomes trial of semaglutide in people with obesity and no diabetes — at 804 clinical sites in 41 countries. Those two numbers do not belong in the same sentence as equals. The incumbent can fund a beachhead. It cannot fund the mountain.
Mitsubishi Tanabe’s oral MC1R agonist, dersimelagon, posted a positive Phase 3 in EPP and X-linked protoporphyria in January 2026. Same shape: a rare phototoxicity indication, a company that knows how to sell to it. Another beachhead. Not the general public.
What a prevention invoice actually looks like
A 2024 analysis in JAMA Network Open put the expected capitalized cost of bringing a dermatology drug through development — failures included, 2018 dollars — at about $680 million. That is an average dermatology program. It is not a decade-long cancer-prevention study in healthy people. The prevention-trial problem is why the real invoice sits above that line: enormous cohorts, a rare-ish endpoint, a safety bar that tightens as the population gets healthier, and regulators who will not let a surrogate finish the claim.
GLP-1 sponsors paid a bill in that neighbourhood because the product at the far end is a chronic prescription that insurers, however reluctantly, can be argued into covering. Obesity became an indication. Weight became a reimbursed outcome. The weekly pen made self-administration ordinary. The commercial thesis was not “people want this.” People wanted fen-phen and every supplement on the shelf. The thesis was “a payer will send us money for years after we prove it.”
A general-public photoprotective has the demand. It does not have the payer. Sunscreen is already the standard of care, it costs pocket change, and no national health system reimburses looking tan. A trial that proved fewer melanomas in fair-skinned adults would be a public-health result of the first order. It would not automatically be a Novo-shaped product. The person who currently buys a $12 bottle of SPF 50 is not a prior-authorization workflow.
That is the part of the GLP-1 parallel this cluster has been polite about. The analogy holds for beachheads, delivery engineering, and the gray market that fills the vacancy. It breaks at reimbursement. Without a payer, the prevention trial is a philanthropy with a protocol number.
The four chairs, and who is sitting in them
The incumbent. Has the approved molecule, the manufacturing, the pharmacovigilance, the regulators on speed-dial. Is spending its surplus on a 200-person vitiligo trial and a cosmetics line. Rational. Wrong shape for “everyone.”
A Novo-scale firm. Has the balance sheet that funds 804-site outcomes work. Already owns the lifestyle-injectable franchise of the decade. Would need a reason to build a melanocortin photoprotective instead of another incretin, and a payer story that is not “it competes with sunscreen.” Nobody has announced that program. Treating the absence as temporary is hope. Treating it as a coincidence is worse.
A dermatology specialty company. Close enough to care about moles and photodamage; not close enough to write SELECT. This is who funds the beachhead rungs that are still empty — transplant recipients, high-UV occupational groups, xeroderma- adjacent populations — if anyone does. A specialty P&L can carry a few thousand high-risk patients. It cannot carry a nation.
A public funder. When commercial sponsors will not run prevention trials, governments sometimes have. The U.S. breast-cancer prevention work on tamoxifen was that kind of bet: a public-health invoice, not a brand. There is no equivalent National Cancer Institute program for a melanocortin photoprotective. The empty chair is data. Public money follows the cancers it has already decided to prevent with drugs it already knows. A new agonist is a harder ask than a drug on the shelf.
The gray market sits in none of these chairs and occupies all of the demand. Enforcement can raise the cost of being a named seller. It cannot sign a protocol.
What would actually move the invoice
Three things, none of them chemistry.
A reimbursable rung wider than EPP and still narrower than “everyone.” Vitiligo is the test already running. If CUV105 works, melanocortin photoprotection will have a second paid indication and a safety file that is no longer only porphyria. If it fails, the beachhead ladder loses a rung and the cosmetics strategy looks, in hindsight, like the honest one. Either result belongs in the Record. Neither is a general-public NDA.
A payer who will cover prevention in a defined high-risk group — transplant, history of melanoma, documented failure to tan — so that the trial has someone to bill at the far end. Without that, you are asking a company to spend SELECT-money to compete with sunscreen.
A public protocol that treats photoprotection as cancer prevention rather than as a lifestyle adjacent to tanning beds. That is a political decision dressed as a scientific one. It has not been made.
Until one of those three exists, the honest answer to “who would pay for the trial” is: no one who currently holds the molecule, and no one who currently holds the checkbook. The vacancy is not a mystery. It is two P&Ls that do not overlap.
Labeled, again
This site’s only opinion is that a tested photoprotective agonist for ordinary people is still worth wanting. That has not changed. What this file adds is the reason wanting has not been enough. The science is not waiting on a eureka. It is waiting on an institution whose math looks like Novo’s and whose asset looks like Scenesse’s. Those have never been the same institution.
The nearest real test is not a thought experiment. It is a vitiligo readout. Watch that. The mountain is still there after it, and so is the invoice.